allcancercure.com

UroToday.com- In the November 2007 issue of the Journal of the National Cancer Institute, Dr. Thall and colleagues report on changing chemotherapy regimens based upon patient response and provide statistical modeling to assess outcomes. They initiated the trial in 1998, prior to the establishment of docetaxel chemotherapy as the first line standard. However, the rationale [...]

The increase in prostate cancer cases in Nordic countries in recent years is consistent with the increased use of PSA testing over the same period. Previous studies examining the relationship between the use of prostate-specific antigen (PSA) testing and prostate cancer mortality have been inconsistent. Rune Kvåle, M.D., of the Cancer Registry of Norway in [...]

A mineral diet supplement that lowers the risk of prostate cancer by 50 percent? While there’s no definitive proof, scientists are intrigued about the connection between prostate cancer risk and selenium, according to the December issue of Mayo Clinic Health Letter. Selenium is a trace mineral that’s essential to good health. While it’s not an [...]

UroToday.com- One-third of men diagnosed with prostate cancer (CaP) will eventually undergo androgen deprivation therapy (ADT). In the October 2007 issue of the Journal of Urology, Dr. Krupski and associates of Dr. Mark Litwin report that men on ADT experience bone complications of osteoporosis and fractures ten increased health care costs. The researchers used the [...]

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced positive results from a newly completed long-term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). 24 clinical trial sites across the U.S. and 103 unselected subjects participated in the blinded, placebo controlled study. The study assessed symptom scores and treatment outcome 2 years (range 16-27 months) after a [...]

African American men face an observable disadvantage versus Caucasian men when it comes to prostate cancer survival. Not only is prostate cancer detected later in African Americans, it is often more aggressive and harder to treat. Findings on the social and biological factors influencing disparities among African American men are reported today at the American [...]

Researchers based at Tulane University report the discovery of biological markers of prostate cancer which are involved in the growth of tumor cells, shedding light on the genetic basis for the prostate cancer burden faced by African-American men. The research is being presented at the American Association for Cancer Research conference on The Science of [...]

Prostate cancer patients often receive treatment that is contraindicated by pre-existing conditions, like urinary or bowel dysfunction, according to a new study. Dr. James Talcott of the Massachusetts General Hospital in Boston and co-investigators found that patients with certain pretreatment dysfunctions often receive contraindicated or “mismatched” therapies, which can lead to worse outcomes. The study [...]

More than a third of men with early prostate cancer who participated in a study analyzing treatment choice received therapies that might not be appropriate, based on pre-existing problems with urinary, bowel or sexual function. The prevalence of these treatment “mismatches” could reflect patient’ unwillingness to discuss such problems with their physicians. The study will [...]

Confirma(R), pioneer and leader in application-specific CAD for MRI, announced the introduction of CADstream for prostate for improved analysis and reporting of the prostate. The prostate application will offer radiologists comprehensive and clinically valuable tools for improved quality, standardization and efficiency of MRI studies. CADstream for prostate will be presented at the upcoming Radiological Society [...]